Palantir Technologies lifts guidance after Q2 results beat Wall Street estimates
Coliseum Capital Management, LLC, along with affiliated entities and individuals, has reported a significant sale of shares in Universal Technical Institute Inc . (NYSE:UTI), a company that has seen its stock surge 84% over the past year. According to the latest SEC filing, Coliseum Capital sold 704,881 shares at a price of $28.20 per share, amounting to a total transaction value of approximately $19.88 million. The stock currently trades near its 52-week high of $30.56, according to InvestingPro data.
Following this sale, the entities involved, including Coliseum Capital Partners (WA:CPAP), L.P., and a separate account investment advisory client, collectively hold over 6.1 million shares. The transactions reflect the ongoing portfolio adjustments by Coliseum Capital, which is known for its active management and investment strategies. With a market capitalization of $1.58 billion and strong analyst consensus, UTI maintains a "Strong Buy" rating with price targets ranging from $31 to $36. The shares are held directly by Coliseum Capital Partners, L.P., and a separate account investment advisory client of Coliseum Capital Management, LLC. Discover more detailed insights and 12 additional key metrics with InvestingPro’s comprehensive analysis.
Christopher Shackelton, who serves as a director of Universal Technical Institute, along with Adam Gray, are managers with ownership interests in Coliseum Capital Management, LLC, and related entities. They have disclaimed beneficial ownership of these securities beyond their pecuniary interests. The company maintains an excellent financial health score according to InvestingPro’s comprehensive analysis, which evaluates multiple financial metrics and growth indicators.
In other recent news, Universal Technical Institute (UTI) has been the subject of recent analyst attention and strategic developments. Rosenblatt Securities has twice increased its price target for UTI stock, first to $30 and then to $36, maintaining a Buy rating each time. The firm cites UTI’s strong performance, including robust corporate partnerships and successful student outcomes, as reasons for the raised target.
UTI also reported a solid fiscal year 2024, with a 21% increase in revenue to $733 million and net income of $42 million. The company plans to continue its growth trajectory in fiscal 2025, projecting revenue between $800-$815 million and introducing new programs and campuses.
In addition, UTI’s Long Beach campus will offer Tesla (NASDAQ:TSLA)’s START Collision Repair program in Spring 2025, marking a significant collaboration. These recent developments suggest a positive outlook for UTI, with analysts and the company itself anticipating continued growth and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.